The effect of nafarelin on human plasma adrenocorticotrophic hormone and cortisol concentrations. 1993

C E Overton, and S H Kennedy, and D E Egan, and D H Barlow
Nuffield Department of Obstetrics & Gynaecology, University of Oxford, John Radcliffe Hospital, UK.

This study assessed the effects on plasma adrenocorticotrophic hormone (ACTH) and cortisol concentrations of 3 months' treatment with intranasal nafarelin 200 micrograms b.d. in 11 women (aged 26-43 years) for the treatment of endometriosis (n = 9), fibroids (n = 1) and pre-menstrual syndrome (n = 1). Serial blood samples were taken over 5 h, before and after nafarelin administration on the first day of treatment, and after 1 and 3 months' treatment. Control samples were taken before and after intranasal placebo administration on the day before nafarelin was commenced. The area under the curve (AUC) for mean ACTH concentrations at each time point from 0 to 240 min was calculated. There were no statistically significant changes in total secretion of either ACTH or cortisol. There was a transient rise in ACTH 30-60 min after nafarelin administration on the first day of treatment in seven out of 11 women. The rise did not exceed the normal range. Seven women with ovarian suppression (oestradiol concentration < 175 pmol/l by day 28) had consistently lower mean ACTH concentrations at all time points than the four remaining women who had oestradiol concentrations 222-880 pmol/l by day 28. Cortisol concentrations were unaffected by nafarelin. We conclude from the results of this study that 3 months' treatment with nafarelin has no effects on adrenal function, as assessed by ACTH and cortisol concentrations.

UI MeSH Term Description Entries
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006854 Hydrocortisone The main glucocorticoid secreted by the ADRENAL CORTEX. Its synthetic counterpart is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Cortef,Cortisol,Pregn-4-ene-3,20-dione, 11,17,21-trihydroxy-, (11beta)-,11-Epicortisol,Cortifair,Cortril,Epicortisol,Hydrocortisone, (11 alpha)-Isomer,Hydrocortisone, (9 beta,10 alpha,11 alpha)-Isomer,11 Epicortisol
D000281 Administration, Intranasal Delivery of medications through the nasal mucosa. Drug Administration, Intranasal,Administration, Intranasal Drug,Administration, Nasal,Intranasal Administration,Intranasal Drug Administration,Administrations, Intranasal,Administrations, Intranasal Drug,Administrations, Nasal,Drug Administrations, Intranasal,Intranasal Administrations,Intranasal Drug Administrations,Nasal Administration,Nasal Administrations
D000311 Adrenal Glands A pair of glands located at the cranial pole of each of the two KIDNEYS. Each adrenal gland is composed of two distinct endocrine tissues with separate embryonic origins, the ADRENAL CORTEX producing STEROIDS and the ADRENAL MEDULLA producing NEUROTRANSMITTERS. Adrenal Gland,Gland, Adrenal,Glands, Adrenal
D000324 Adrenocorticotropic Hormone An anterior pituitary hormone that stimulates the ADRENAL CORTEX and its production of CORTICOSTEROIDS. ACTH is a 39-amino acid polypeptide of which the N-terminal 24-amino acid segment is identical in all species and contains the adrenocorticotrophic activity. Upon further tissue-specific processing, ACTH can yield ALPHA-MSH and corticotrophin-like intermediate lobe peptide (CLIP). ACTH,Adrenocorticotropin,Corticotropin,1-39 ACTH,ACTH (1-39),Adrenocorticotrophic Hormone,Corticotrophin,Corticotrophin (1-39),Corticotropin (1-39),Hormone, Adrenocorticotrophic,Hormone, Adrenocorticotropic
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D017274 Nafarelin A potent synthetic agonist of GONADOTROPIN-RELEASING HORMONE with 3-(2-naphthyl)-D-alanine substitution at residue 6. Nafarelin has been used in the treatments of central PRECOCIOUS PUBERTY and ENDOMETRIOSIS. Nafarelin Acetate,Nafarelin Acetate, Hydrate,Nafarelin Monoacetate,RS-94991-298,Synarel,RS 94991 298,RS94991298

Related Publications

C E Overton, and S H Kennedy, and D E Egan, and D H Barlow
January 1982, European journal of clinical pharmacology,
C E Overton, and S H Kennedy, and D E Egan, and D H Barlow
January 2006, Clinical chemistry and laboratory medicine,
C E Overton, and S H Kennedy, and D E Egan, and D H Barlow
April 1989, Drug and alcohol dependence,
C E Overton, and S H Kennedy, and D E Egan, and D H Barlow
May 2020, Journal of veterinary internal medicine,
C E Overton, and S H Kennedy, and D E Egan, and D H Barlow
October 1980, The Journal of clinical endocrinology and metabolism,
C E Overton, and S H Kennedy, and D E Egan, and D H Barlow
April 2003, European journal of applied physiology,
C E Overton, and S H Kennedy, and D E Egan, and D H Barlow
June 1986, Clinical pharmacology and therapeutics,
C E Overton, and S H Kennedy, and D E Egan, and D H Barlow
November 1984, General and comparative endocrinology,
Copied contents to your clipboard!